IBB Dividend Yield 2026: iShares Biotechnology ETF

The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.

Data last updated: Oct 28, 2026

Dividend Yield: 0.16%

Years of Dividend History: 20

About iShares Biotechnology ETF Dividend

The iShares Biotechnology ETF dividend reflects a fund built to track the performance of publicly traded U.S. biotechnology companies. IBB currently yields 0.17%, with a trailing annual dividend rate of $0.3399 per share paid quarterly. The next ex-dividend date is September 15, 2026. At a beta of 0.713, IBB stock carries below-average price volatility, which appeals to investors who want biotechnology exposure without the full swing of individual biotech names.

Dividend Safety

iShares Biotechnology ETF pays out dividends as a pass-through from its underlying holdings, making a traditional payout ratio not applicable (fund/ETF). iShares Biotechnology ETF dividend safety depends on the distributions generated by the U.S. biotechnology companies the fund tracks, not on a single company's earnings. The most significant pressure point is that biotech sector income can be lumpy, and the fund's history shows at least one year-over-year decline exceeding 5%, which means the payout level is not guaranteed to hold in any given year.

iShares Biotechnology ETF (IBB) Dividend Growth Rate, CAGR, and History

iShares Biotechnology ETF dividend history shows a CAGR of 4.3% per year from 2012 to 2023. Per-share payments grew from $0.2188 to $0.3480 over that window (2024 and 2025 figures are partial years and excluded from the rate calculation). The largest single-year jump was 96.7% in 2017, but that spike is an outlier, not a baseline, and the fund has posted year-over-year declines within the same period.

iShares Biotechnology ETF Dividend Growth Rate (CAGR)

Period	CAGR	From	To
3-Year	-1.8%	$0.41 (2022)	$0.39 (2025)
5-Year	+4.5%	$0.31 (2020)	$0.39 (2025)
10-Year	+28.8%	$0.03 (2015)	$0.39 (2025)

Is iShares Biotechnology ETF a Good Dividend Stock?

IBB fits dividend investors who want biotechnology sector exposure and can accept a low (below 2%) yield as a secondary feature rather than the primary draw. At 0.17%, the current yield sits just below the 5-year average of 0.18%, so there is no meaningful yield expansion on offer. The fund has two consecutive years of dividend increases, a modest streak that does not anchor income expectations. What an investor gets is diversified access to U.S. biotech stocks with below-average price volatility; what they give up is any meaningful income stream from the dividend alone.

Recent iShares Biotechnology ETF Dividend Payments

Payment Date	Amount per Share
2026-09-15	$0.0112
2026-06-15	$0.0238
2026-03-17	$0.1218
2025-12-16	$0.1831
2025-09-16	$0.0828
2025-03-18	$0.1212
2024-12-17	$0.0624
2024-09-25	$0.2005
2024-03-21	$0.1260
2023-12-20	$0.1240

iShares Biotechnology ETF Annual Dividend History

Year	Total Dividends
2026	$0.1568
2025	$0.3871
2024	$0.3889
2023	$0.3480
2022	$0.4090

Frequently Asked Questions

What is IBB's dividend yield?

iShares Biotechnology ETF (IBB) currently yields 0.16% based on the annual dividend rate and today's share price.

Has iShares Biotechnology ETF ever cut its dividend?

The available history shows at least one year-over-year decline exceeding 5% within the 2012 to 2023 window, so the iShares Biotechnology ETF dividend has not been perfectly linear. The data does not cover periods before 2012, so no claim can be made about the full history.

How fast has iShares Biotechnology ETF grown its dividend?

IBB has grown its dividend at a compound annual growth rate (CAGR) of 4.3% per year from 2012 to 2023. Per-share payments rose from $0.2188 to $0.3480 over that period, though individual years varied widely.

Is iShares Biotechnology ETF a good dividend stock for income investors?

At a 0.17% yield, iShares Biotechnology ETF is a low-income payer by any standard measure. Dividend investors who prioritize current income will find the yield too thin; the fund's appeal lies in biotechnology sector exposure, not dividend generation.

What type of investor is iShares Biotechnology ETF best suited for?

IBB suits investors who want diversified U.S. biotechnology exposure with below-average price volatility (beta of 0.713) and can treat the 0.17% dividend as incidental rather than a core income source.

Why is iShares Biotechnology ETF dividend yield low?

The yield is low because the underlying U.S. biotechnology companies the fund tracks tend to reinvest earnings into research and development rather than paying large dividends. The annual dividend rate of $0.3399 per share simply does not produce a meaningful yield at current price levels.

Project income from IBB with the IBB dividend calculator or track your full portfolio with the dividend tracker.